Antiviral Drugs - D-A-CH

D-A-CH

The Antiviral Drugs market in D-A-CH is expected to witness significant growth in the coming years.
According to projections, the revenue is projected to reach US$2.05bn in 2024.
Furthermore, it is anticipated that the market will exhibit a steady annual growth rate (CAGR 2024-2029) of 1.70%, leading to a market volume of US$2.23bn by 2029.
When compared to other countries globally, United States is expected to generate the highest revenue in the Antiviral Drugs market, with an estimated revenue of US$30,640.00m in 2024.
In Germany, there is a growing demand for antiviral drugs due to the country's emphasis on preventive healthcare and high healthcare spending.

Key regions: Brazil, India, Australia, United States, United Kingdom

Market

Region

Region comparison

Currency

Analyst Opinion

The demand for antiviral drugs in D-A-CH has been steadily increasing over the years.

Customer preferences: Customers in D-A-CH have become more health-conscious, leading to an increased demand for antiviral drugs. Additionally, the aging population in the region has also contributed to the growth of the market.

Trends in the market: The antiviral drugs market in D-A-CH is witnessing a shift towards the development of new drugs that target specific viral strains. This is due to the increasing prevalence of viral infections that are resistant to traditional antiviral drugs. Furthermore, there is a growing trend towards the use of combination therapies that involve the use of multiple antiviral drugs to treat viral infections.

Local special circumstances: Germany is the largest market for antiviral drugs in D-A-CH. The German government has implemented policies to encourage the development of new drugs and increase access to antiviral treatments. Switzerland has a strong pharmaceutical industry and is home to several major pharmaceutical companies that are involved in the development of antiviral drugs. Austria has a smaller market for antiviral drugs but has a high demand for treatments for hepatitis C.

Underlying macroeconomic factors: The healthcare industry in D-A-CH is well-developed and has a high level of government support. The region has a high per capita income, which allows for greater affordability of antiviral drugs. The region also has a strong research and development sector, which has contributed to the development of new antiviral drugs. Additionally, the region has a high level of healthcare infrastructure, which has facilitated the growth of the antiviral drugs market.

Methodology

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.